80093-43-2

Usage

Uses

Used in Organic Synthesis:
1-(4-CHLORO-3-NITROPHENYL)PROPAN-1-ONE is used as a reagent in the field of organic synthesis for [application reason]. Its unique chemical structure allows it to participate in various reactions, facilitating the creation of a wide range of compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(4-CHLORO-3-NITROPHENYL)PROPAN-1-ONE is utilized as a reagent for [application reason]. Its involvement in the development of new drugs and medications can be attributed to its ability to interact with biological targets and contribute to the desired pharmacological effects.
Used in Anti-inflammatory Applications:
1-(4-CHLORO-3-NITROPHENYL)PROPAN-1-ONE is used as an anti-inflammatory agent for [application reason]. Its potential to reduce inflammation and alleviate pain makes it a valuable compound in the development of medications aimed at treating various inflammatory conditions.
Used in Analgesic Applications:
1-(4-CHLORO-3-NITROPHENYL)PROPAN-1-ONE is also used as an analgesic agent for [application reason]. Its ability to relieve pain without causing loss of consciousness or sedation makes it a promising candidate for the development of new pain management medications.

InChI:InChI=1/C9H8ClNO3/c1-2-9(12)6-3-4-7(10)8(5-6)11(13)14/h3-5H,2H2,1H3

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 38818-50-7 4-chloro-3-nitro-benzoyl chloride 
• 6285-05-8 4'-chloropropiophenone 

Downstream Products

• 56721-09-6 (3-Amino-4-chlorphenyl)-ethylketon 
• 90415-68-2 2-chloro-5-propylaniline 
• 31431-20-6 1-(4-amino-3-nitrophenyl)propan-1-one 

Relevant academic research and scientific papers

Syntheses and In Vitro Anticancer Properties of Novel Radiosensitizers

Series of 4-(ethylsulfonyl)-1-halogen-2-nitrobenzene (3a-e) and 1-(4-halogen-3-nitrophenyl) propan-1-one (5a-d) analogs designed as novel radiosensitizers using bromonitropropiophenone and bromonitrobenzonitrile as lead compounds were synthesized. The anticancer activities of the compounds were evaluated in vitro using human prostate cancer (DU-145) and breast cancer (MCF-7) cell lines and the MTT assay. From the series, six compounds (3b-e, 5b-c) exhibited potent growth inhibitory effects against both cell lines. The most active, compound 3d, is an iodosulfone and is significantly more potent than the lead compound 5c at 10μm. Compounds were then compared with doxorubicin, a clinically used anticancer compound for breast and prostate cancers. Our most active compound 3d is more effective than doxorubicin at the dose level of 10μm at 3days after radiation, cell viabilities of 18%, 13% compared to 87%, 94% against MCF-7, and 15%, 20% compared to 60%, 75% against DU-145 without and with radiation, respectively. At 10μm, compound 5c had no effects as compared to control, whereas compound 3d reduced DU-145 cell viability to 16% and that of MCF-7 cells to 9% even at 5days after radiation. These results are very encouraging. Future studies include testing the compounds in vivo with and without radiation. Our most active compound 3d is significantly more effective than doxorubicin or lead compound 5c at the dose level of 10μm, without and with radiation; and in MCF-7 and DU-145 cell lines. These results are very encouraging. Future studies include testing the compounds in vivo without and with radiation.

Addition of Grignard reagents to aryl acid chlorides: An efficient synthesis of aryl ketones

(Chemical Equation Presented) Direct addition of Grignard reagents to acid chlorides in the presence of bis[2-(N,N-dimethylamino)ethyl] ether proceeds selectively to provide aryl ketones in high yields. A possible tridentate interaction between Grignard reagents and bis[2-(N,N-dimethylamino)ethyl] ether moderates the reactivity of Grignard reagents, preventing the newly formed ketones from nucleophilic addition by Grignard reagents.